U.S. Markets closed

China SXT Pharmaceuticals, Inc. (SXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3698+0.0081 (+2.24%)
At close: 4:00PM EDT

0.3630 -0.01 (-1.84%)
After hours: 7:52PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3617
Open0.3580
Bid0.3625 x 3200
Ask0.3689 x 900
Day's Range0.3482 - 0.4041
52 Week Range0.3400 - 2.8000
Volume13,970,970
Avg. Volume6,106,092
Market Cap22.239M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government
    PR Newswire

    China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a fund granted to the Company for the key techniques incorporated into advanced Directly-Oral TCMPs derived from agriculture has been approved on February 19, 2020, by the Hailing District Science and Technology Bureau of Taizhou city.

  • China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory
    PR Newswire

    China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory

    China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that its DNA Exam Laboratory completely built in October of 2019 recently has been approved by Jiangsu province Drug Administration (JSDA). The Laboratory has been granted to perform research and development (R&D;) and quality control of TCM raw materials and TCMP products applying DNA testing technology.

  • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
    PR Newswire

    China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

    China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 27, 2019 the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).